General Surgery Department, Shanxi Bethune Hospital/Third Hospital of Shanxi Medical University, Taiyuan, China.
School of Nursing/Research Center of Dietary Therapy Technology, Shanxi Medical University, Taiyuan, China.
Lipids Health Dis. 2023 Aug 29;22(1):137. doi: 10.1186/s12944-023-01900-5.
Nonalcoholic fatty liver disease (NAFLD) is a prevalent chronic liver disorder worldwide. According to several previous studies, the treatment of patients with NAFLD using medicinal and food-homologous substances has consistent effects on the levels of blood lipids and blood glucose and liver function.
This systematic review was conducted to investigate the impact of medicinal and food homologous substances on blood lipid and glucose levels as well as liver function in patients with NAFLD.
A thorough search was conducted in eight databases, including China Science and Technology Journal Database (VIP), Chinese National Knowledge Infrastructure(CNKI), China Biomedical Literature Database (SinoMed), Wanfang Database, PubMed, Cochrane Library, Web of Science and Embase, for articles published from database inception until June 24, 2023. The methodological quality of the included studies was evaluated utilizing Cochrane Randomized Trial Risk Bias Tool, Edition 2 and GRADE methodology for assessment.
A total of 13 randomized controlled trials, involving 829 patients with NAFLD, were included in the analysis, these studies included a total of 9 medicinal and food homologous substances. In the 13 studies, hawthorn (2), sea buckthorn (1), ginger (2), turmeric (4) (1 with chicory seeds), cinnamon (1), cardamom (1), purslane (1) and saffron (1) were included. The results of the included studies showed that medicinal and food homologous substances could improve high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TGs), fasting blood glucose (FBG) and liver enzyme levels in patients with NAFLD to a certain extent, but the effect of turmeric on TC, liver enzyme levels is controversial.
In patients with NAFLD, dietary intervention using medicinal and food homologous substances can ameliorate blood lipid and blood glucose levels and liver enzymes to some extent. In clinical work, medicinal and food homologous substances can be used to provide patients with NAFLD with a safe and effective dietary plan to help prevent and treat disease onset and progression.
非酒精性脂肪性肝病(NAFLD)是一种全球范围内普遍存在的慢性肝脏疾病。根据几项先前的研究,使用药食同源物质治疗 NAFLD 患者对血脂和血糖水平以及肝功能具有一致的影响。
本系统评价旨在研究药食同源物质对 NAFLD 患者血脂和血糖水平及肝功能的影响。
在中国科技期刊数据库(VIP)、中国知网(CNKI)、中国生物医学文献数据库(SinoMed)、万方数据库、PubMed、Cochrane 图书馆、Web of Science 和 Embase 等 8 个数据库中进行全面检索,检索时间从数据库建库至 2023 年 6 月 24 日。采用 Cochrane 偏倚风险评估工具评估纳入研究的方法学质量,并采用 GRADE 方法评估。
共纳入 13 项随机对照试验,涉及 829 例 NAFLD 患者,这些研究共涉及 9 种药食同源物质。13 项研究中,涉及山楂(2)、沙棘(1)、生姜(2)、姜黄(4)(1 项研究与菊苣籽联合应用)、肉桂(1)、小豆蔻(1)、马齿苋(1)和藏红花(1)。纳入研究的结果表明,药食同源物质在一定程度上可以改善 NAFLD 患者的高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、三酰甘油(TGs)、空腹血糖(FBG)和肝酶水平,但姜黄对 TC、肝酶水平的影响存在争议。
在 NAFLD 患者中,药食同源物质的饮食干预在一定程度上可以改善血脂和血糖水平以及肝酶。在临床工作中,可使用药食同源物质为 NAFLD 患者提供安全有效的饮食方案,以帮助预防和治疗疾病的发生和进展。